Profile banner
Bhupesh Dewan

Bhupesh Dewan

Director of Medical Services at Zuventus Healthcare Limited

bhupesh-dewan
Mumbai, Maharashtra, India
Joined May 2026
Favicon imagezuventus.com
Favicon imageresearchgate.net

Network

6.4K connections
👑
Zuventus Sales Leadership
📈
Pharma Sales Managers
💡
Pharma Marketing Leaders
🤝
Zuventus Operations HR
💊
Zuventus Marketing Product
🔬
Zuventus Clinical R&D
⚕️
...

Summary

Experienced clinical research leader: Dr. Dewan has participated in and overseen a large volume of clinical research activity, including involvement in over 100 clinical trials and authorship/co-authorship of multiple clinical study reports and journal articles. researchgate+2
Regulatory and product introduction expertise: He has substantial Indian regulatory experience, including conducting more than 50 product-related meetings with the Drug Controller General of India (DCGI), and experience interacting with international regulatory authorities (USFDA and EMEA); he has been involved in introducing over 20 products for the first time in India. zuventus
Active in medical communications and education: Dr. Dewan has conducted extensive medical education activities, participating in and delivering product-related lectures and contributing to over 1500 Continuous Medical Education (CME) sessions in India and abroad. zuventus
Broad drug-development and therapeutic experience: At Zuventus he is described as pivotal in development across diverse therapeutic areas, including work on 'chiral' molecules and multiple post-marketing studies and Phase IV trials. zuventus+1

Work

Education

Projects

Writing

Evaluating the safety, tolerability, and efficacy of tulobuterol transdermal patch in patients with asthma or chronic obstructive pulmonary disease: A phase-IV clinical study

August 1, 2025

Phase-IV multicentric study evaluating safety, tolerability, and efficacy of a tulobuterol transdermal patch (Tuloplast™) in asthma and COPD patients, reporting favorable safety and improvements in symptom control and lung function.

Favicon imagepubmed.ncbi.nlm.nih.gov

An Open-Label, Multicenter Post Marketing Study to Assess the Symptomatic Efficacy and Safety of Troxipide (TroxipTM) in the Management of Acid Peptic Disorders in Indian Patients

January 1, 2013

Multicenter, observational post-marketing study of Troxipide 100 mg in Indian patients with acid peptic disorders, reporting symptomatic efficacy and safety across 62 centers.

Favicon imagejournaljammr.com

An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition

Bioequivalence study comparing two lafutidine 10 mg formulations (test vs reference) under fasting conditions, reporting pharmacokinetic parameters and concluding bioequivalence.

Favicon imagepmc.ncbi.nlm.nih.gov